Abstract Materials innovation is reshaping healthcare, from next‐generation drug delivery to breakthrough implantable devices. Yet, concerns over toxicity and stringent regulations, especially in inorganic materials and nanotechnology, often stifle progress, limiting the exploration of novel solutions. Despite these hurdles, emerging discoveries underscore the untapped potential of unconventional materials in medicine. Unlocking this potential requires a proactive, science‐driven approach to safety. This paper outlines key strategies to bridge innovation and regulation, including early‐stage toxicological screening, interdisciplinary co‐design, computational modeling, life cycle impact analysis, and robust post‐market surveillance. By embedding these principles into materials development, the healthcare industry can push the boundaries of medical technology while ensuring uncompromising safety and efficacy.
Herrmann et al. (Wed,) studied this question.